STOCK TITAN

Haemonetics accounting chief sells 836 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Haemonetics Corp. (HAE) VP, Chief Accounting Officer Farris Maryanne Maunsell exercised options for 1,068 shares at $89.16, 645 shares at $95.73, and 433 shares at $70.31 on November 11, 2026, acquiring the corresponding common shares. She also delivered or had withheld 1,724 shares for payment of exercise price or tax liability, and sold 836 shares at a weighted average price of $120.99 in multiple transactions ranging from $120.87 to $121.10. No Rule 10b5-1 plan is reported.

Insider Maunsell Farris Maryanne
Role VP, Chief Accounting Officer
Sold 836 shs ($101K)
Approx. gross sale proceeds $101K
Approx. exercise cost $187K
Share of Position Sold 12.5%
Type Security Shares Price Value
Exercise Non-qualified Stock Option (Right to Buy) F4 1,068 $0.00 $0.00
Exercise Non-qualified Stock Option (Right to Buy) F4 645 $0.00 $0.00
Exercise Non-qualified Stock Option (Right to Buy) F4 433 $0.00 $0.00
Exercise Common Stock F1 1,068 $89.16 $95K
Exercise Common Stock F1 645 $95.73 $62K
Exercise Common Stock F1 433 $70.31 $30K
Exercise Price or Tax Liability Common Stock F2, F1 1,724 $121.10 $209K
Sale Common Stock F3, F1 836 $120.99 $101K
Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 2,302 options (Direct); Common Stock — 5,828 shares (Direct)
Holdings Before and After: Non-qualified Stock Option (Right to Buy), 4,448 to 2,302 options (Direct); Common Stock, 6,242 to 5,828 shares (Direct)
Footnotes (4)
  1. F1. This number includes unvested restricted stock units ("RSUs") previously reported.
  2. F2. Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.87 to $121.10, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
  4. F4. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
Options exercised 1,068 shares Exercise price: $89.16 per share; November 11, 2026
Options exercised 645 shares Exercise price: $95.73 per share; November 11, 2026
Options exercised 433 shares Exercise price: $70.31 per share; November 11, 2026
Shares delivered or withheld 1,724 shares For payment of exercise price or tax liability; November 11, 2026
Shares sold 836 shares November 11, 2026
Weighted average sale price $120.99 per share Multiple transactions at prices from $120.87 to $121.10
Option vesting 25% annual increments Beginning on the first anniversary of the grant date
Non-qualified Stock Option (Right to Buy) technical
"the options exercised for common shares"
weighted average price financial
"the price for shares sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
restricted stock units financial
"shares previously reported include unvested restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise price financial
"shares delivered or withheld for option exercise price or tax obligations"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many HAE shares did Farris Maryanne Maunsell sell, and at what price?

Maunsell sold 836 Haemonetics common shares on November 11, 2026, at a weighted average price of $120.99. The shares were sold in multiple transactions at prices from $120.87 to $121.10. No Rule 10b5-1 plan is reported.

How do Farris Maryanne Maunsell’s Haemonetics options vest?

The options vest in annual increments of 25%, beginning on the first anniversary of the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Maunsell Farris Maryanne

(Last)(First)(Middle)
125 SUMMER STREET

(Street)
BOSTON MASSACHUSETTS 02110

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
VP, Chief Accounting Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/11/2026M1,068A$89.167,310(1)D
Common Stock11/11/2026M645A$95.737,955(1)D
Common Stock11/11/2026M433A$70.318,388(1)D
Common Stock11/11/2026F1,724(2)D$121.16,664(1)D
Common Stock11/11/2026S836D$120.99(3)5,828(1)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-qualified Stock Option (Right to Buy)$89.1611/11/2026M1,068 (4)05/15/2030Common Stock1,068$0357D
Non-qualified Stock Option (Right to Buy)$95.7311/11/2026M645 (4)05/17/2031Common Stock645$0646D
Non-qualified Stock Option (Right to Buy)$70.3111/11/2026M433 (4)05/16/2032Common Stock433$01,299D
Explanation of Responses:
1. This number includes unvested restricted stock units ("RSUs") previously reported.
2. Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.87 to $121.10, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
4. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
/s/ Thomas V. Powers, attorney-in-fact for Ms. Farris11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading